Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
- TD Cowen 4th Annual Oncology Innovation Summit on Tuesday, May 30, 2023 at 8:30 AM ET (virtual)
-
Jefferies Healthcare Conference on Thursday, June 8, 2023 at 2:30 PM ET in
New York, NY
A live webcast of both events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005134/en/
Investor Relations:
Maghan Meyers
Argot Partners
Deciphera@argotpartners.com
212-600-1902
Media:
David Rosen
Argot Partners
david.rosen@argotpartners.com
212-600-1902
Source: Deciphera Pharmaceuticals, Inc.
